R. Delva

960 total citations
23 papers, 582 citations indexed

About

R. Delva is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, R. Delva has authored 23 papers receiving a total of 582 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 10 papers in Cancer Research and 8 papers in Pulmonary and Respiratory Medicine. Recurrent topics in R. Delva's work include Cancer Treatment and Pharmacology (9 papers), Breast Cancer Treatment Studies (8 papers) and Testicular diseases and treatments (5 papers). R. Delva is often cited by papers focused on Cancer Treatment and Pharmacology (9 papers), Breast Cancer Treatment Studies (8 papers) and Testicular diseases and treatments (5 papers). R. Delva collaborates with scholars based in France, Switzerland and Spain. R. Delva's co-authors include Armelle Caty, Christine Chevreau, Patricia de Crémoux, Xavier Pivot, G. Milano, Jean‐Yves Pierga, Armelle Degeorges, Marie-Christine Étienne-Grimaldi, Corinne Veyret and Stéphane Culine and has published in prestigious journals such as Journal of Clinical Oncology, British Journal of Cancer and Annals of Oncology.

In The Last Decade

R. Delva

23 papers receiving 566 citations

Peers

Countries citing papers authored by R. Delva

Since Specialization

Citations

This map shows the geographic impact of R. Delva's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by R. Delva with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites R. Delva more than expected).

Fields of papers citing papers by R. Delva

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by R. Delva. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by R. Delva. The network helps show where R. Delva may publish in the future.

Co-authorship network of co-authors of R. Delva

This figure shows the co-authorship network connecting the top 25 collaborators of R. Delva. A scholar is included among the top collaborators of R. Delva based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with R. Delva. R. Delva is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	713P Assessment of bleomycin pulmonary toxicity in men with poor-prognosis non-seminomatous germ-cell tumors treated in the GETUG 13 phase III trial 2021 ·Annals of Oncology ·(unknown), Gwénaël Le Teuff, Lance C. Pagliaro, Aude Fléchon, Jozef Mardiak, Lionnel Geoffrois, Pierre Kerbrat, Christine Chevreau, R. Delva, Frédéric Rolland, Christine Théodore, Guilhem Roubaud, Gwénaëlle Gravis, (unknown), (unknown), Claude Linassier, Mária Rečková, Soazig Nénan, Stéphane Culine, Karim Fizazi	1
2	Neuroendocrine carcinoma of the urinary bladder: A large analysis of the French GETUG consortium 2018 ·Annals of Oncology ·(unknown), (unknown), Magalie P. Tardy, (unknown), (unknown), R. Delva, (unknown), Pernelle Lavaud, Y. Neuzillet, Nicolas Penel, Nadine Houédé, Damien Pouessel, (unknown), M. Gross Goupil, H. Gauthier, Aurélien Gobert, Olivier Huillard, Yves Allory, (unknown), Stéphane Oudard	1
3	Use of liposomal doxorubicin–cyclophosphamide combination in breast cancer patients with brain metastases: a monocentric retrospective study 2014 ·Journal of Neuro-Oncology ·B. Linot, Mario Campone, Paule Augereau, R. Delva, Sophie Abadie‐Lacourtoisie, (unknown), Olivier Capitain	15
4	A Risk-adapted Study of Cisplatin and Etoposide, with or Without Ifosfamide, in Patients with Metastatic Seminoma: Results of the GETUG S99 Multicenter Prospective Study 2013 ·European Urology ·Karim Fizazi, R. Delva, Armelle Caty, Christine Chevreau, Pierre Kerbrat, Frédéric Rolland, Frank Priou, Lionnel Geoffrois, Olivier Rixe, Philippe Beuzeboc, Jean-Pierre Malhaire, Stéphane Culine, (unknown), Agnès Laplanche	30
5	First-line bevacizumab-containing therapy for breast cancer: results in patients aged ≥70 years treated in the ATHENA study 2011 ·Annals of Oncology ·Laura Biganzoli, (unknown), Zefei Jiang, Mikhail Lichinitser, (unknown), R. Delva, Natalia Bogdanova, Guillermo López-Vivanco, (unknown), Ying Cheng, Marianne Just, Marc Espié, J. Vinholes, Caroline Hamm, Diana Crivellari, Ewa Chmielowska, Semiglazov Vf, Florence Dalenc, Ian Smith	44
6	High rate of extra-haematological toxicity compromises dose-dense sequential adjuvant chemotherapy for breast cancer 2011 ·British Journal of Cancer ·Étienne Brain, Christelle Lévy, D. Serin, Henri Roché, M. Spielmann, R. Delva, Corinne Veyret, L. Mauriac, María Rios, Anne‐Laure Martin, M. Carolina Jimenez, Bernard Asselain, M. Gauthier, Franck Bonnetain, P. Fumoleau	6
7	Assessing 2-month clinical prognosis in patients with solid tumors: First results of PRONOPALL study. 2011 ·Journal of Clinical Oncology ·Hugues Bourgeois, S Traoré, Philippe Solal‐Céligny, Olivier Dupuis, P. Maillart, Olivier Capitain, R. Delva, P Soulié, M. Marcq, Éveline Boucher, G. Ganem, Emmanuelle Bourbouloux, (unknown), Mehdi Kaassis, (unknown), (unknown), Virginie Berger, (unknown), Pierre Ingrand, (unknown)	1
8	Clinical value of circulating endothelial cells and circulating tumor cells in metastatic breast cancer patients treated first line with bevacizumab and chemotherapy 2010 ·Annals of Oncology ·François‐Clément Bidard, Claire Mathiot, Armelle Degeorges, Marie-Christine Étienne-Grimaldi, R. Delva, Xavier Pivot, Corinne Veyret, Laurence Bergougnoux, Patricia de Crémoux, G. Milano, Jean‐Yves Pierga	119
9	Prospective analysis of the impact of VEGF‐A gene polymorphisms on the pharmacodynamics of bevacizumab‐based therapy in metastatic breast cancer patients 2010 ·British Journal of Clinical Pharmacology ·Marie-Christine Étienne-Grimaldi, Patricia Formento, Armelle Degeorges, Jean‐Yves Pierga, R. Delva, Xavier Pivot, Florence Dalenc, Marc Espié, Corinne Veyret, (unknown), M Francoual, (unknown), Patricia de Crémoux, G. Milano	56
10	The value of early decrease in CA125 levels as a prognostic or surrogate marker for disease progression in patients with recurrent ovarian cancer: Results from the CALYPSO study. 2010 ·Journal of Clinical Oncology ·R. J. Simes, (unknown), Mansoor Raza Mirza, Philippe Sauthier, Apostolos P. Georgopoulos, Ignace Vergote, Gabriella Ferrandina, Nicoletta Donadello, Barbara Schmalfeldt, R. Delva	2
11	A risk-adapted study of cisplatin and etoposide, with or without ifosfamide, in patients with metastatic seminoma: Results of the GETUG S99 multicenter prospective study 2009 ·Journal of Clinical Oncology ·Karim Fizazi, (unknown), R. Delva, Christine Chevreau, Armelle Caty, Pierre Kerbrat, F. Rolland, Frank Priou, A. Laplanche	2
12	Refining the optimal chemotherapy regimen for good-risk metastatic nonseminomatous germ-cell tumors: a randomized trial of the Genito-Urinary Group of the French Federation of Cancer Centers (GETUG T93BP) 2007 ·Annals of Oncology ·Stéphane Culine, Pierre Kerbrat, A. Kramar, Christine Théodore, Christine Chevreau, Lionnel Geoffrois, N.B. Bui, J Pény, Armelle Caty, R. Delva, Pierre Biron, Karim Fizazi, J. Bouzy, Jean‐Pierre Droz	122
13	Sequential Addition of an Anthracycline-Based Regimen to Docetaxel as Neoadjuvant Chemotherapy in Patients with Operable Breast Cancer 2006 ·Clinical Breast Cancer ·S. Amat, Marie‐Ange Mouret‐Reynier, Frédérique Penault‐Llorca, Marianne Leheurteur, R. Delva, Bruno Coudert, Bernard Leduc, J Dauplat, Hervé Curé, P. Chollet	3
14	High Prognostic Significance of Residual Disease After Neoadjuvant Chemotherapy: a Retrospective Study in 710 Patients with Operable Breast Cancer 2006 ·Breast Cancer Research and Treatment ·Catherine Abrial, Frédérique Penault‐Llorca, R. Delva, Philippe Bougnoux, Bernard Leduc, Marie‐Ange Mouret‐Reynier, D. Méry-Mignard, Jean‐Pierre Bleuse, J Dauplat, Hervé Curé, P. Chollet	4
15	Tumor Parameters, Clinical and Pathological Responses, Medical Management, and Survival Through Time on 710 Operable Breast Cancers 2005 ·Medical Oncology ·Catherine Abrial, Marie‐Ange Mouret‐Reynier, S. Amat, (unknown), Philippe Bougnoux, R. Delva, H. Curé, J Dauplat, Frédérique Penault‐Llorca, P. Chollet	5
16	Pathological and Clinical Response of a Primary Chemotherapy Regimen Combining Vinorelbine, Epirubicin, and Paclitaxel as Neoadjuvant Treatment in Patients with Operable Breast Cancer 2005 ·The Oncologist ·Catherine Abrial, Isabelle Van Praagh, R. Delva, Bernard Leduc, Joël Fleury, Érick Gamelin, (unknown), Frédérique Penault‐Llorca, S. Amat, P. Chollet	9
17	High prognostic significance of residual disease after neoadjuvant chemotherapy: a retrospective study in 710 patients with operable breast cancer 2005 ·Breast Cancer Research and Treatment ·Catherine Abrial, Frédérique Penault‐Llorca, R. Delva, Philippe Bougnoux, Bernard Leduc, Marie‐Ange Mouret‐Reynier, D. Méry-Mignard, Jean‐Pierre Bleuse, J Dauplat, Hervé Curé, P. Chollet	84
18	[Isolated peritoneal metastases from an lobular infiltrating breast carcinoma. Value of laparoscopy]. 1998 ·PubMed ·É. Fondrinier, Olivier Guérin, R. Delva, (unknown)	1
19	Rapidly recycled, intensive alternating chemotherapy in heavily pretreated progressive nonseminomatous germ cell tumors a feasibility study 1995 ·Urologic Oncology Seminars and Original Investigations ·Stéphane Culine, Jean‐Pierre Droz, R. Delva, B. Bui, Armelle Caty, (unknown), (unknown), M Mousseau	5
20	[Ambulatory blood pressure in normotensive subjects. Definition of reference values as a function of age by the Spacelabs instrument]. 1987 ·PubMed ·(unknown), R. Delva, (unknown), Gilles Châtellier, C Battaglia, C Devriès, (unknown), Pierre Corvol, Julie Ménard	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact